|
|
Office Locations:
|
757 Third Avenue, 21st Floor
New York, NY 10017
Phone: 212-319-5555
Fax: 212-319-5591
| | |
|
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
|
KBL is a venture capital firm dedicated to investing in early stage and emerging growth healthcare companies. The firm's goal is to identify companies that are run by seasoned management teams and that have the potential to create long term value. Major areas of investment include life sciences, medical devices, healthcare services and medical information technology. Within the life sciences space, KBL will invest in biopharmaceuticals, drug discovery platforms and advanced materials. Within the medical device area, KBL seeks companies addressing large, unmet medical needs with demonstrated clinical benefit. In July 2007, KBL completed a $138 million IPO led by Citi to target a merger with a healthcare or healthcare-related business. KBL Merger Corp. IV completed its IPO in June 2017, raising $115 million with the goal of identifying and acquiring a company with a strong value proposition mainly in the U.S. healthcare or the healthcare-related wellness industry.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
